Media & Investors

Media & Investors

This section of the Akcea Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Akcea Therapeutics​ assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQAKCA
Beta--
Shares Outstanding101.5M
Average Volume (10 days)196.9K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.29)
Sales (TTM)$3.36
Book Value (MRQ)$5.02
Cash Flow (TTM)$1.04
Cash (MRQ)$4.17

Analyst Views

Current Mean RecommendationBuy
Strong Buy2
 
Buy0
 
Hold2
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Joshua Patterson
General Counsel
12,500
Acquire
Apr 15, 2020
Kyle Jenne
Chief Commercial Officer
(779)
Sell
Mar 23, 2020
Joshua Patterson
General Counsel
(335)
Sell
Mar 23, 2020
Damien McDevitt
Director, Chief Executive Officer
(9,417)
Sell
Mar 23, 2020
Louis O'Dea
Chief Medical Officer
(3,198)
Sell
Mar 23, 2020

Recent SEC Filings

S-8
May 21, 2020
Insider Buy/Sell
May 19, 2020
New Insider
May 19, 2020
Company Events
May 18, 2020
Quarterly Financials
May 6, 2020